We are live on ! Find out more
BPMC

Blueprint Medicines

Delisted

BPMC was delisted on the 17th of July, 2025.

73 hedge funds and large institutions have $474M invested in Blueprint Medicines in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,855% more call options, than puts

Call options by funds: $19.6M | Put options by funds: $197K

61% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 18

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

4% more funds holding

Funds holding: 7073 (+3)

7% less capital invested

Capital invested by funds: $509M → $474M (-$35.3M)

Holders
73
Holders Change
+3
Holders Change %
+4.29%
% of All Funds
1.92%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
13
Increased
29
Reduced
18
Closed
9
Calls
$19.6M
Puts
$197K
Net Calls
+$19.4M
Net Calls Change
+$19.4M
Name Holding Trade Value Shares
Change
Change in
Stake
GL
76
GLG LLC
New York
-$640K -30,000 Closed
GP
77
GLG Partners
United Kingdom
-$573K -26,858 Closed
VKH
78
Virtu KCG Holdings
New York
-$212K -9,922 Closed
Royal Bank of Canada
79
Royal Bank of Canada
Ontario, Canada
-$9.14K -406 -97%
TRCT
80
Tower Research Capital (TRC)
New York
-$8K -353 Closed
MGIA
81
Moneta Group Investment Advisors
Missouri
-$2K -100 Closed
TWMP
82
Taylor Wealth Management Partners
Massachusetts
-$1K -56 Closed

BPMC Hedge Fund Activity: Q4 2015 in Review

73 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2015, worth a combined $474M — down 6.9% from $509M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new BPMC positions and 9 closed out — a net gain of 4 holders — while 29 added to existing stakes and 18 trimmed.

The largest buyer was Fidelity International, opening a new position worth an estimated $18.1M. The largest seller was Wellington Management Group, cutting an estimated $17.8M.

  • 73 institutional investors held Blueprint Medicines (BPMC) as of Q4 2015, up from 70 in Q3 2015.
  • Funds reported $474M of Blueprint Medicines stock for Q4 2015, down 6.9% quarter-over-quarter.
  • 13 funds opened new Blueprint Medicines positions in Q4 2015 and 9 closed out, a net change of +4 holders.
  • The largest Blueprint Medicines buyer in Q4 2015 was Fidelity International, an estimated $18.1M added.
  • The largest Blueprint Medicines seller in Q4 2015 was Wellington Management Group, an estimated $17.8M sold.

Based on aggregated 13F filings for Q4 2015.